Post‐transplant monomorphic Burkitt's lymphoma: Clinical characteristics and outcome of a multicenter series

word count: 233 words Text word count: 2363 words Number of figures: 2

[1]  G. Salles,et al.  Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Heitjan,et al.  The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  G. Verhoef,et al.  Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern , 2015, Haematologica.

[4]  S. Yip,et al.  Burkitt-like post-transplant lymphoproliferative disorder (PTLD) presenting with breast mass in a renal transplant recipient: a report of a rare case , 2014, Annals of Hematology.

[5]  L. Staudt,et al.  Low-intensity therapy in adults with Burkitt's lymphoma. , 2013, The New England journal of medicine.

[6]  P. Moreau,et al.  Tumour lysis syndrome and acute kidney injury in high‐risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco‐Hématologique , 2013, British journal of haematology.

[7]  J. Esteve,et al.  Dose‐intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status , 2013, Cancer.

[8]  G. Verleden,et al.  Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors , 2013, Leukemia & lymphoma.

[9]  D. Lenze,et al.  Burkitt post‐transplantation lymphoma in adult solid organ transplant recipients , 2012, Cancer.

[10]  D. Linch,et al.  Burkitt lymphoma in adults , 2012, British journal of haematology.

[11]  G. Salles,et al.  Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. , 2012, The Lancet. Oncology.

[12]  T. Rausch,et al.  PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis , 2012, Case reports in medicine.

[13]  M. Saggese,et al.  RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma , 2012, British journal of haematology.

[14]  G. Mazariegos,et al.  Post‐transplant Burkitt lymphoma is a more aggressive and distinct form of post‐transplant lymphoproliferative disorder , 2011, Cancer.

[15]  D. Heitjan,et al.  Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder ★ , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  R. Marcus,et al.  Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines , 2010, British journal of haematology.

[17]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[18]  J. Briones,et al.  Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease , 2007, Haematologica.

[19]  B. Dörken,et al.  Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution , 2007, Annals of Hematology.

[20]  H. Kantarjian,et al.  Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.

[21]  B. Dörken,et al.  Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD) , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  G. Klein,et al.  Burkitt lymphoma. , 2009, Seminars in cancer biology.

[23]  J. Delabie,et al.  Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  P. Papenhausen,et al.  Burkitt Lymphoma Arising in Organ Transplant Recipients: A Clinicopathologic Study of Five Cases , 2003, The American journal of surgical pathology.

[25]  D. Porter,et al.  Post-transplant lymphoproliferative disorder: a review , 2003, Bone Marrow Transplantation.

[26]  J. Esteve,et al.  Post-transplant Burkit t's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial) , 2003, Leukemia & lymphoma.

[27]  M. Yacoub,et al.  Epstein-Barr virus associated Burkitt lymphoma in a heart transplant recipient. , 1996, Transplantation.

[28]  T. Starzl,et al.  Malignant lymphomas in transplantation patients. , 1969, Transplantation proceedings.

[29]  A. Webster,et al.  Post-transplant lymphoproliferative disorders , 2016, Nature Reviews Disease Primers.

[30]  M. Slovak,et al.  Late onset of EBV-driven PTLD/Burkitt lymphoma/leukemia in a patient 10 years after allogeneic stem cell transplant for AML , 2010, Bone Marrow Transplantation.

[31]  A. Tzakis,et al.  Burkitt’s lymphoma variant of post-transplant lymphoproliferative disease (PTLD) , 2009, Pathology Oncology Research.

[32]  A. Rickinson,et al.  Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. , 2007, Hematology. American Society of Hematology. Education Program.

[33]  J. Esteve,et al.  Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. , 2003, Haematologica.